Finished
Signia Stapler Versus Vessel Sealer Extend Energy Device With SureForm Stapling in Robotic-Assisted Segmentectomy
NCT05727735 · St. Joseph's Healthcare Hamilton · Updated 31 July 2024
- What is being tested
- Medtronic Signia Stapler; Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling
- For
- Lung Cancer; Thoracic Cancer; Lung Neoplasm
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 120 years. About 56 people. The full rules are on the registry page.
- Where
- Canada
- When
- Starts or started 14 April 2023, ends 30 April 2024. Registered 14 Feb 2023.
- Results
- None posted yet.
In the researchers' words
Robotic-assisted thoracoscopic surgery (RTS) segmentectomy is safe and effective for patients with early-stage non-small cell lung cancer (NSCLC). In RTS-segmentectomy, dissection and sealing procedures are performed by either staplers or energy devices. Staplers, the current standard of care, have been associated with higher operating costs compared to energy devices for open lobectomy, RTS lobectomy and minimally invasive segmentectomy. However, there is a lack of prospective research evaluating the costs of the two methods for lung dissection and vessel sealing in RTS-segmentectomy. This prospective trial seeks to determine whether it is feasible to conduct a randomized controlled trial evaluating the costs of the Signia stapler versus Vessel Sealer Extend energy device in RTS-segmentectomy for NSCLC. If this trial is feasible, we will be able to conduct a full-scale trial to compare costs and health outcomes, providing an economic evaluation that will inform hospital decision makers and clinicians in Canada.
Sites
- St. Joseph's Healthcare HamiltonHamilton, Ontario, Canada
